Concepts (231)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cytomegalovirus | 12 | 2019 | 49 | 2.530 |
Why?
|
| Pericytes | 4 | 2019 | 21 | 1.960 |
Why?
|
| Cytomegalovirus Infections | 5 | 2019 | 28 | 1.560 |
Why?
|
| Herpesvirus 8, Human | 9 | 2011 | 29 | 1.260 |
Why?
|
| Kidney Glomerulus | 3 | 2019 | 85 | 1.220 |
Why?
|
| Sarcoma, Kaposi | 5 | 2011 | 24 | 1.080 |
Why?
|
| Kidney Diseases | 2 | 2019 | 170 | 1.040 |
Why?
|
| Vaginosis, Bacterial | 2 | 2016 | 8 | 0.860 |
Why?
|
| Host-Pathogen Interactions | 2 | 2019 | 203 | 0.860 |
Why?
|
| Cytokines | 6 | 2019 | 661 | 0.800 |
Why?
|
| Virus Replication | 5 | 2019 | 318 | 0.760 |
Why?
|
| Papillomavirus Vaccines | 1 | 2025 | 168 | 0.750 |
Why?
|
| Mesangial Cells | 2 | 2019 | 9 | 0.700 |
Why?
|
| Podocytes | 2 | 2018 | 37 | 0.670 |
Why?
|
| Papillomavirus Infections | 1 | 2025 | 363 | 0.660 |
Why?
|
| Placenta | 2 | 2019 | 113 | 0.640 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 680 | 0.630 |
Why?
|
| BK Virus | 1 | 2019 | 4 | 0.620 |
Why?
|
| Polyomavirus Infections | 1 | 2019 | 18 | 0.620 |
Why?
|
| Trophoblasts | 2 | 2020 | 31 | 0.580 |
Why?
|
| 5' Untranslated Regions | 1 | 2018 | 20 | 0.560 |
Why?
|
| Chorionic Villi | 1 | 2017 | 5 | 0.550 |
Why?
|
| Postoperative Complications | 1 | 2019 | 253 | 0.540 |
Why?
|
| Blood-Retinal Barrier | 1 | 2017 | 11 | 0.530 |
Why?
|
| Eye Diseases | 1 | 2017 | 26 | 0.520 |
Why?
|
| Brain | 3 | 2015 | 1452 | 0.510 |
Why?
|
| Retina | 2 | 2019 | 288 | 0.500 |
Why?
|
| Genome, Viral | 6 | 2009 | 118 | 0.490 |
Why?
|
| Cells, Cultured | 8 | 2017 | 1617 | 0.480 |
Why?
|
| Skin Neoplasms | 2 | 2023 | 175 | 0.480 |
Why?
|
| Fibroblasts | 1 | 2017 | 278 | 0.480 |
Why?
|
| Humans | 33 | 2025 | 42163 | 0.440 |
Why?
|
| Blood-Brain Barrier | 2 | 2013 | 167 | 0.430 |
Why?
|
| Up-Regulation | 2 | 2012 | 534 | 0.380 |
Why?
|
| Gardnerella vaginalis | 1 | 2011 | 2 | 0.370 |
Why?
|
| Vagina | 1 | 2011 | 89 | 0.360 |
Why?
|
| Down-Regulation | 2 | 2011 | 452 | 0.350 |
Why?
|
| Calcium-Binding Proteins | 1 | 2011 | 80 | 0.340 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2011 | 78 | 0.340 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 138 | 0.340 |
Why?
|
| HIV-1 | 2 | 2016 | 747 | 0.330 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2011 | 165 | 0.330 |
Why?
|
| Galectin 3 | 1 | 2009 | 29 | 0.320 |
Why?
|
| Multigene Family | 1 | 2009 | 105 | 0.310 |
Why?
|
| Epithelial Cells | 1 | 2011 | 426 | 0.290 |
Why?
|
| Kidney Transplantation | 3 | 2019 | 102 | 0.280 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2018 | 196 | 0.270 |
Why?
|
| Phylogeny | 3 | 2009 | 740 | 0.260 |
Why?
|
| Endothelium, Vascular | 3 | 2019 | 261 | 0.240 |
Why?
|
| Pregnancy | 4 | 2020 | 1737 | 0.230 |
Why?
|
| Tennessee | 1 | 2025 | 88 | 0.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 933 | 0.220 |
Why?
|
| Particulate Matter | 1 | 2025 | 80 | 0.210 |
Why?
|
| Endothelial Cells | 3 | 2013 | 324 | 0.210 |
Why?
|
| Female | 10 | 2025 | 24018 | 0.210 |
Why?
|
| Air Pollutants | 1 | 2025 | 127 | 0.200 |
Why?
|
| Fibronectins | 2 | 2015 | 69 | 0.200 |
Why?
|
| Animals | 13 | 2025 | 16695 | 0.190 |
Why?
|
| Vaccination | 1 | 2025 | 332 | 0.190 |
Why?
|
| Environmental Exposure | 1 | 2025 | 247 | 0.190 |
Why?
|
| Molecular Sequence Data | 13 | 2009 | 1559 | 0.190 |
Why?
|
| Antigens, Viral | 3 | 2009 | 50 | 0.190 |
Why?
|
| Rural Population | 1 | 2025 | 352 | 0.180 |
Why?
|
| Melanoma | 1 | 2023 | 109 | 0.180 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 928 | 0.180 |
Why?
|
| HIV Infections | 1 | 2016 | 2535 | 0.180 |
Why?
|
| Fetal Membranes, Premature Rupture | 1 | 2020 | 8 | 0.170 |
Why?
|
| Decidua | 1 | 2020 | 8 | 0.170 |
Why?
|
| Gene Expression Regulation, Viral | 3 | 2015 | 115 | 0.170 |
Why?
|
| Amnion | 1 | 2020 | 16 | 0.170 |
Why?
|
| Streptococcus | 1 | 2020 | 18 | 0.170 |
Why?
|
| Stromal Cells | 1 | 2020 | 54 | 0.170 |
Why?
|
| Streptococcal Infections | 1 | 2020 | 36 | 0.170 |
Why?
|
| Immediate-Early Proteins | 4 | 2002 | 50 | 0.160 |
Why?
|
| Amino Acid Sequence | 10 | 2009 | 1188 | 0.160 |
Why?
|
| Virus Activation | 1 | 2019 | 38 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 649 | 0.150 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 101 | 0.150 |
Why?
|
| Interferon-beta | 1 | 2018 | 9 | 0.140 |
Why?
|
| Chemokine CCL5 | 1 | 2018 | 40 | 0.140 |
Why?
|
| Vero Cells | 2 | 2017 | 109 | 0.140 |
Why?
|
| Viral Proteins | 6 | 2003 | 196 | 0.140 |
Why?
|
| Open Reading Frames | 5 | 2007 | 81 | 0.130 |
Why?
|
| Coculture Techniques | 1 | 2017 | 105 | 0.130 |
Why?
|
| Genes, Viral | 6 | 2009 | 64 | 0.130 |
Why?
|
| Neurons | 2 | 2015 | 1246 | 0.130 |
Why?
|
| Macrophages | 1 | 2020 | 515 | 0.120 |
Why?
|
| Sequence Alignment | 4 | 2009 | 273 | 0.120 |
Why?
|
| Causality | 1 | 2016 | 45 | 0.120 |
Why?
|
| Nocardia asteroides | 1 | 1995 | 1 | 0.120 |
Why?
|
| Risk Assessment | 1 | 2019 | 845 | 0.120 |
Why?
|
| Genes, Bacterial | 1 | 1995 | 92 | 0.120 |
Why?
|
| Inflammation | 1 | 2020 | 729 | 0.120 |
Why?
|
| Adult | 2 | 2025 | 13458 | 0.120 |
Why?
|
| Macaca mulatta | 4 | 1996 | 139 | 0.110 |
Why?
|
| Superoxide Dismutase | 1 | 1995 | 158 | 0.110 |
Why?
|
| Vimentin | 1 | 2015 | 38 | 0.110 |
Why?
|
| Antigens | 1 | 2015 | 58 | 0.110 |
Why?
|
| Proteoglycans | 1 | 2015 | 49 | 0.110 |
Why?
|
| Visual Pathways | 1 | 2015 | 40 | 0.110 |
Why?
|
| Cell Adhesion Molecules | 1 | 2015 | 84 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 4 | 2002 | 534 | 0.110 |
Why?
|
| Green Fluorescent Proteins | 1 | 2015 | 207 | 0.110 |
Why?
|
| Young Adult | 1 | 2025 | 4936 | 0.110 |
Why?
|
| Neuroglia | 1 | 2015 | 131 | 0.110 |
Why?
|
| Cerebrospinal Fluid | 1 | 2013 | 20 | 0.110 |
Why?
|
| Recombinant Proteins | 2 | 2011 | 522 | 0.110 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 137 | 0.110 |
Why?
|
| Nuclear Proteins | 2 | 2009 | 330 | 0.100 |
Why?
|
| Adolescent | 1 | 2025 | 5950 | 0.100 |
Why?
|
| Cell Line, Tumor | 2 | 2011 | 2598 | 0.100 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2013 | 33 | 0.100 |
Why?
|
| Virulence | 2 | 2011 | 238 | 0.100 |
Why?
|
| Base Sequence | 8 | 2002 | 997 | 0.100 |
Why?
|
| Steroid Hydroxylases | 1 | 2011 | 3 | 0.090 |
Why?
|
| Receptors, Chemokine | 2 | 2002 | 72 | 0.090 |
Why?
|
| Astrocytes | 1 | 2013 | 244 | 0.090 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 51 | 0.090 |
Why?
|
| Tropoelastin | 1 | 2011 | 13 | 0.090 |
Why?
|
| RNA, Messenger | 2 | 2015 | 1265 | 0.090 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2011 | 160 | 0.090 |
Why?
|
| Microscopy, Confocal | 1 | 2011 | 223 | 0.090 |
Why?
|
| Neuroprotective Agents | 1 | 2013 | 267 | 0.080 |
Why?
|
| Genetic Variation | 4 | 2007 | 429 | 0.080 |
Why?
|
| Risk Factors | 1 | 2019 | 3942 | 0.080 |
Why?
|
| Trans-Activators | 2 | 2002 | 190 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 2 | 2009 | 506 | 0.080 |
Why?
|
| Microcirculation | 1 | 2009 | 40 | 0.080 |
Why?
|
| Middle Aged | 1 | 2025 | 11819 | 0.080 |
Why?
|
| Gene Duplication | 1 | 2009 | 24 | 0.080 |
Why?
|
| Tissue Array Analysis | 1 | 2009 | 79 | 0.080 |
Why?
|
| Cell Line | 4 | 2009 | 1416 | 0.080 |
Why?
|
| Viral Load | 1 | 2011 | 344 | 0.080 |
Why?
|
| Chemokines, CXC | 1 | 2009 | 36 | 0.080 |
Why?
|
| Primates | 1 | 2009 | 38 | 0.080 |
Why?
|
| Male | 4 | 2025 | 22779 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 3 | 2003 | 508 | 0.080 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2009 | 88 | 0.070 |
Why?
|
| Hela Cells | 1 | 2009 | 370 | 0.070 |
Why?
|
| DNA, Viral | 6 | 1999 | 323 | 0.070 |
Why?
|
| Evolution, Molecular | 1 | 2009 | 299 | 0.070 |
Why?
|
| Polymorphism, Genetic | 2 | 2007 | 200 | 0.060 |
Why?
|
| Herpesviridae Infections | 2 | 2007 | 18 | 0.060 |
Why?
|
| United States | 3 | 2023 | 5072 | 0.050 |
Why?
|
| Pan troglodytes | 1 | 2003 | 21 | 0.050 |
Why?
|
| SEER Program | 1 | 2023 | 157 | 0.050 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2002 | 22 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2002 | 38 | 0.050 |
Why?
|
| Skin | 1 | 2023 | 185 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 512 | 0.050 |
Why?
|
| Virus Assembly | 1 | 2001 | 44 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 4 | 2007 | 454 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 2020 | 67 | 0.040 |
Why?
|
| Toll-Like Receptors | 1 | 2020 | 51 | 0.040 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2020 | 95 | 0.040 |
Why?
|
| DNA Replication | 1 | 2001 | 153 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2020 | 237 | 0.040 |
Why?
|
| Simian immunodeficiency virus | 2 | 1990 | 61 | 0.040 |
Why?
|
| Cloning, Molecular | 2 | 2001 | 318 | 0.040 |
Why?
|
| Elephants | 1 | 1999 | 2 | 0.040 |
Why?
|
| Herpesviridae | 1 | 1999 | 12 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2001 | 169 | 0.040 |
Why?
|
| Transcriptional Activation | 2 | 1990 | 173 | 0.040 |
Why?
|
| Animals, Zoo | 1 | 1999 | 15 | 0.040 |
Why?
|
| Recombination, Genetic | 1 | 1999 | 96 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2025 | 1554 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2001 | 228 | 0.040 |
Why?
|
| Species Specificity | 2 | 1997 | 279 | 0.040 |
Why?
|
| Viral Envelope Proteins | 1 | 1999 | 90 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2020 | 379 | 0.040 |
Why?
|
| Alleles | 1 | 1999 | 352 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 1997 | 98 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2020 | 355 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2001 | 557 | 0.030 |
Why?
|
| Genotype | 3 | 2007 | 796 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2023 | 2485 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2001 | 722 | 0.030 |
Why?
|
| Paraquat | 1 | 1995 | 21 | 0.030 |
Why?
|
| Genetic Complementation Test | 1 | 1995 | 57 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 1999 | 548 | 0.030 |
Why?
|
| Herbicides | 1 | 1995 | 44 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1993 | 90 | 0.030 |
Why?
|
| Blotting, Western | 1 | 1995 | 884 | 0.030 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 1993 | 57 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2020 | 2111 | 0.020 |
Why?
|
| HIV | 1 | 1990 | 100 | 0.020 |
Why?
|
| Africa | 2 | 1999 | 81 | 0.020 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2007 | 44 | 0.020 |
Why?
|
| Chromosome Mapping | 2 | 1999 | 198 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 1999 | 271 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 2002 | 599 | 0.020 |
Why?
|
| RNA, Viral | 2 | 2002 | 317 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2002 | 42 | 0.010 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2002 | 72 | 0.010 |
Why?
|
| Virus Latency | 1 | 2002 | 49 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2002 | 154 | 0.010 |
Why?
|
| Penicillium | 1 | 2001 | 7 | 0.010 |
Why?
|
| Viral Core Proteins | 1 | 2001 | 13 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 221 | 0.010 |
Why?
|
| Fungal Proteins | 1 | 2001 | 143 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2002 | 400 | 0.010 |
Why?
|
| Genes, Overlapping | 1 | 1999 | 2 | 0.010 |
Why?
|
| Transfection | 1 | 2001 | 526 | 0.010 |
Why?
|
| Saudi Arabia | 1 | 1999 | 7 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2002 | 960 | 0.010 |
Why?
|
| Taiwan | 1 | 1999 | 21 | 0.010 |
Why?
|
| Inclusion Bodies, Viral | 1 | 1999 | 4 | 0.010 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 1999 | 26 | 0.010 |
Why?
|
| Endodeoxyribonucleases | 1 | 1999 | 29 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2001 | 383 | 0.010 |
Why?
|
| Asia | 1 | 1999 | 99 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2001 | 222 | 0.010 |
Why?
|
| Hemorrhage | 1 | 1999 | 55 | 0.010 |
Why?
|
| Thymidylate Synthase | 1 | 1998 | 3 | 0.010 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 1 | 1998 | 9 | 0.010 |
Why?
|
| Genes, Immediate-Early | 1 | 1997 | 11 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1997 | 29 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 1998 | 165 | 0.010 |
Why?
|
| Plasmids | 1 | 1997 | 247 | 0.010 |
Why?
|
| Introns | 1 | 1996 | 80 | 0.010 |
Why?
|
| Exons | 1 | 1996 | 91 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 1997 | 295 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 1996 | 136 | 0.010 |
Why?
|
| Binding Sites | 1 | 1996 | 670 | 0.010 |
Why?
|
| Superinfection | 1 | 1990 | 2 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1990 | 36 | 0.010 |
Why?
|
| HIV Long Terminal Repeat | 1 | 1990 | 20 | 0.010 |
Why?
|
| Gene Products, tat | 1 | 1990 | 36 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1990 | 116 | 0.000 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 1990 | 55 | 0.000 |
Why?
|
| Mice | 1 | 1990 | 6490 | 0.000 |
Why?
|